Find therapies in clinical trials near you – page 105

Study on the Effects and Safety of Upadacitinib for Children with Polyarticular Juvenile Idiopathic Arthritis

Study on the Effects and Safety of Upadacitinib for Children with Polyarticular Juvenile Idiopathic Arthritis

Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Study on Ganaxolone for Patients with Refractory Status Epilepticus

Study on Ganaxolone for Patients with Refractory Status Epilepticus

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Study on BI 764524 for Patients with Moderate to Severe Diabetic Retinopathy

Study on BI 764524 for Patients with Moderate to Severe Diabetic Retinopathy

Study on the Safety and Tolerability of Olaparib in Children and Adolescents with Solid Tumors

Study on the Safety and Tolerability of Olaparib in Children and Adolescents with Solid Tumors

Study on the Safety of Avacincaptad Pegol for Patients with Geographic Atrophy Who Completed a Previous Study

Study on the Safety of Avacincaptad Pegol for Patients with Geographic Atrophy Who Completed a Previous Study

Study on VE202 for Patients with Mild-to-Moderate Ulcerative Colitis

Study on VE202 for Patients with Mild-to-Moderate Ulcerative Colitis

Study of Rocatinlimab in Adults with Prurigo Nodularis Not Adequately Controlled by Topical Treatments

Study of Rocatinlimab in Adults with Prurigo Nodularis Not Adequately Controlled by Topical Treatments

Study on Norucholic Acid for Treating Primary Sclerosing Cholangitis in Patients

Study on Norucholic Acid for Treating Primary Sclerosing Cholangitis in Patients

Study of cabozantinib with atezolizumab compared to sorafenib in untreated patients with advanced liver cancer (hepatocellular carcinoma)

Study on Nemolizumab for Children Aged 2-11 with Moderate-to-Severe Atopic Dermatitis Not Controlled by Topical Treatments

Study on Nemolizumab for Children Aged 2-11 with Moderate-to-Severe Atopic Dermatitis Not Controlled by Topical Treatments